Widespread clinical adoption of NOTCH3-ECD testing has the future potential to transform the IPAH diagnosis and management landscape, enabling possibly earlier treatment and improved outcomes. Here, NOTCH3 is linked to idiopathic pulmonary arterial hypertension.